.webp?width=217&height=60&name=Screenpoint-Med%20(1).webp "Screen Point Medical")
%20(1).png)
MASAI RCT: 12% reduction in interval cancer rate using Transpara
.png)
Transpara® Breast AI Selected for $16M PRISM Randomized Controlled Trial in USA
.png)
ScreenPoint Medical Enables Transpara® Breast AI within Precision Imaging Network, part of Microsoft for Healthcare
Discussing AI findings in the patient record
Dr. Rachel Brem explores how providers might think about AI findings - including breast imaging - in the patient record and where she landed on the topic.
.png)
Breast AI + Tomosynthesis: The Perfect Match
Dr. Ben Pettus discusses how Breast AI complements digital breast tomosynthesis, making radiologists both more accurate and more efficient.
%20(1).png)
What's the best AI for breast cancer detection (for your screening program)?
Considering your options for breast cancer AI can be difficult; this guide and vendor comparison chart makes it simpler to differentiate and decide.
.png)
New book from Joanna Stern highlights personal breast cancer journey
Journalist and tech writer Joanna Stern explores how AI is changing how radiologists catch cancer earlier and more effectively for women worldwide.
What MASAI reinforces about AI in USA screening mammography
What can results from the MASAI randomised controlled trial tell us about the state of breast AI research in screening mammography in the United States?
ScreenPoint Medical Secures $16M to Lead the Next Phase of AI in Breast Cancer Care
ScreenPoint Medical announces $16 million investment from existing partners and research grants to fuel growth and build toward personalized care.